Literature DB >> 12732644

RASSF2 is a novel K-Ras-specific effector and potential tumor suppressor.

Michele D Vos1, Chad A Ellis, Candice Elam, Aylin S Ulku, Barbara J Taylor, Geoffrey J Clark.   

Abstract

Ras proteins regulate a wide range of biological processes by interacting with a broad assortment of effector proteins. Although activated forms of Ras are frequently associated with oncogenesis, they may also provoke growth-antagonistic effects. These include senescence, cell cycle arrest, differentiation, and apoptosis. The mechanisms that underlie these growth-inhibitory activities are relatively poorly understood. Recently, two related novel Ras effectors, NORE1 and RASSF1, have been identified as mediators of apoptosis and cell cycle arrest. Both of these proteins exhibit many of the properties normally associated with tumor suppressors. We now identify a novel third member of this family, designated RASSF2. RASSF2 binds directly to K-Ras in a GTP-dependent manner via the Ras effector domain. However, RASSF2 only weakly interacts with H-Ras. Moreover, RASSF2 promotes apoptosis and cell cycle arrest and is frequently down-regulated in lung tumor cell lines. Thus, we identify RASSF2 as a new member of the RASSF1 family of Ras effectors/tumor suppressors that exhibits a specificity for interacting with K-Ras.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12732644     DOI: 10.1074/jbc.M300554200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  69 in total

1.  Prognostic importance of RASSF2 expression in patients with gastric cancer who had undergone radical gastrectomy.

Authors:  D Aydin; A Bilici; S Kayahan; D Yavuzer; M Basar; M Aliustaoglu
Journal:  Clin Transl Oncol       Date:  2015-10-12       Impact factor: 3.405

Review 2.  Intracellular and intercellular signaling networks in cancer initiation, development and precision anti-cancer therapy: RAS acts as contextual signaling hub.

Authors:  Peter Csermely; Tamás Korcsmáros; Ruth Nussinov
Journal:  Semin Cell Dev Biol       Date:  2016-07-06       Impact factor: 7.727

Review 3.  Regulation of mammalian Ste20 (Mst) kinases.

Authors:  Sonali J Rawat; Jonathan Chernoff
Journal:  Trends Biochem Sci       Date:  2015-02-06       Impact factor: 13.807

4.  RASSF2A promoter methylation in hepatitis B virus-related hepatocellular carcinogenesis and its correlation with elevated serum alpha-fetoprotein level.

Authors:  Jinghua Ren; Wenshan He; Ruiguang Zhang; Zhenyu Li; Wenmiao Cao; Jie Yao; Fang Zhu; Tao Zhang; Gang Wu
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2009-06-10

5.  Ras history: The saga continues.

Authors:  Adrienne D Cox; Channing J Der
Journal:  Small GTPases       Date:  2010-07

6.  Ras, an actor on many stages: posttranslational modifications, localization, and site-specified events.

Authors:  Imanol Arozarena; Fernando Calvo; Piero Crespo
Journal:  Genes Cancer       Date:  2011-03

7.  Ras isoform abundance and signalling in human cancer cell lines.

Authors:  J Omerovic; D E Hammond; M J Clague; I A Prior
Journal:  Oncogene       Date:  2007-11-12       Impact factor: 9.867

Review 8.  Ras oncogenes: split personalities.

Authors:  Antoine E Karnoub; Robert A Weinberg
Journal:  Nat Rev Mol Cell Biol       Date:  2008-07       Impact factor: 94.444

9.  Integrating multiple microarray data for cancer pathway analysis using bootstrapping K-S test.

Authors:  Bing Han; Xue-Wen Chen; Xinkun Wang; Elias K Michaelis
Journal:  J Biomed Biotechnol       Date:  2009-05-26

10.  Methylation associated inactivation of RASSF1A and its synergistic effect with activated K-Ras in nasopharyngeal carcinoma.

Authors:  Tao Wang; Hongli Liu; Yeshan Chen; Wei Liu; Jing Yu; Gang Wu
Journal:  J Exp Clin Cancer Res       Date:  2009-12-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.